Against this backdrop, mwb research is hosting an online roundtable with Boris Polenxke (CEO) on June 16, 2026, at 2:00 p.m. CEST. Following a presentation, there will be an opportunity to ask questions. The event is aimed at professional investors and semi-professional private investors and will take place online in German. Participation is free of charge; login details will be provided after registration at https://research-hub.de/events/registration/2026-06-16-14-00/123F-GR.

Siltronic’s re-rating has been fueled by the broader AI-driven chip rally and improving leading-edge 300mm wafer demand, with normalized logic/memory inventories and early signs of more reasonable 300mm spot pricing adding credibility to the recovery narrative. However, we think the market is moving faster than the earnings base: power inventories remain a drag, evidence of a broad-based pricing inflection is still limited, and elevated depreciation alongside a high debt burden should constrain the earnings recovery. We therefore reiterate SELL, while raising our PT to EUR 65.00 to reflect a better medium-term visibility throughout the cycle and gradually improving end-market demand. The full update can be downloaded under https://research-hub.de/companies/siltronic-ag

Geratherm’s has reported FY25 results. Revenues increased by 6%, but severe macroeconomic headwinds, Chinese competition, and domestic cost pressures compressed the EBIT margin to 0.6%, resulting in a net loss of EUR -0.15 per share after a EUR 1.1m securities impairment. Despite the loss, management proposed a stable dividend of EUR 0.10, backed by a strong liquidity position and positive cash flow from good working capital management. For FY26, management guides for flat revenues and a negative EBIT during a transition period focused on addressing structural deficiencies, especially in Healthcare Diagnostics. Considering these ongoing challenges, we downgrade our estimates, leading to a new PT of EUR 4.50 (old: EUR 6.00), still supporting our BUY recommendation. The full update can be downloaded under https://research-hub.de/companies/geratherm-medical-ag

America First adds another layer of uncertainty to STRATEC’s investment case, but the impact should be indirect rather than immediate. Recent investment cuts by Eli Lilly and Boehringer highlight a more politicized pharma and healthcare capital-allocation backdrop, although STRATEC is not primarily exposed to pharma production capex. As an OEM partner for diagnostic systems, software and consumables, the key risk is that diagnostics and life-science customers delay new platform decisions, serial-production transfers or supply-chain commitments amid tariffs, localization pressure and policy uncertainty. After a weak Q1 26, FY26 and mainly H2 remains execution dependent. But according to recent news flow from lager diagnostic players, visibility remains low. Therefore, we keep our cautious ‘show me first’-stance, even the recent share price set-back could offer an attractive entry point. With estimates and a price target of EUR 20.00 unchanged, we remain HOLD. The full update can be downloaded under https://research-hub.de/companies/stratec-se

Company Name: MaaT Pharma SACA ISIN: FR0012634822   Reason for the research: Update Recommendation: Under review from: 11.06.2026 Target price: Under review Target price on sight of: - Last rating change: - Analyst: Christian Orquera First Berlin Equity Research has published a research update on MaaT Pharma SACA (ISIN: FR001263 [ … ]

Frasers Group has moved HUGO BOSS into M&A territory. Within two days, the UK retailer first de-escalated its governance stance by backing Supervisory Board Chairman Stephan Sturm and welcoming the adjusted dividend policy, before announcing its intention to launch an unsolicited voluntary takeover offer at EUR 38.00 per share. Frasers is already an active anchor shareholder with around 25% and board representation, making the bid a further step in its push for influence. While the offer may create a short-term valuation floor, we view it as opportunistic and financially unattractive for long-term shareholders. HOLD confirmed. The full update can be downloaded under https://research-hub.de/companies/hugo-boss-ag

Ennoconn has crossed the 30% voting-rights threshold in Kontron, triggering a mandatory offer at EUR 23.50 per share. We see the offer as a regulatory consequence of Ennoconn strengthening its anchor-shareholder role, not as a fair-value benchmark. The fundamental upside case remains intact, driven by Defense, Transportation/Rail and the emerging Cybersecurity software opportunity. We reiterate BUY and our EUR 34.00 PT. Kontron CFO Clemens Billek will present at our virtual Industrial Technology Conference on 22 June 2026, followed by Q&A. Please register here: https://research-hub.de/conference/industrial-technology The full update can be downloaded under https://research-hub.de/companies/kontron-ag

EDAG has announced a EUR 75m financing package consisting of a EUR 50m capital increase and a EUR 25m mandatory convertible loan provided by its major shareholder ATON Austria Holding GmbH. The transaction includes 12.5m new shares at EUR 4.00 and a further 6.25m shares via conversion, lifting ATON’s stake from 74.66% to around 85.52%. We view the capital injection positively as it strengthens the balance sheet, reduces leverage concerns, and increases financial flexibility to support both the core automotive engineering business and the expansion in the defense segment. However, it comes at the cost of significant dilution, with the share count rising by around 75% and estimated economic dilution of about 40% for minority shareholders. The higher ownership concentration also raises potential takeover considerations. We lower our PT to EUR 4.00 from EUR 6.50 while maintaining BUY given remaining upside potential. The full update can be downloaded under https://research-hub.de/companies/edag-engineering-group-ag

Recent news on Nvidia’s co-packaged optics / 800V DC roadmap and China-linked InP export delays suggests that the near-term ramp-up may be capped: demand could remain focused on existing optical architectures for longer, while constrained InP substrate availability may reduce the need for additional tool capacity. Despite our constructive medium-term view on AI photonics, co-packaged optics and 800V DC opportunities, we believe the recent share-price rally has run ahead of visible fundamentals, underpinning our SELL rating and EUR 40.00 price target. The full update can be downloaded under https://research-hub.de/companies/aixtron-se

HMS Bergbau plans to issue a new five-year bond of up to EUR 50m at an 8.0% coupon, following last year’s EUR 75m bond at 10.0%. Proceeds are intended to support further growth in commodity trading and were not reflected in HMS’ FY26 guidance issued in May. Assuming full placement and 6x annual capital turnover, the bond could support c. EUR 300m of additional trading volume and c. EUR 6m EBITDA annually. We view the transaction positively, as growth is strongly working-capital driven. Estimates remain unchanged for now. PT EUR 80.00, BUY. The full update can be downloaded under https://research-hub.de/companies/hms-bergbau-ag